EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Why and when could nucleos(t)ide analogues treatment be withdrawn?

Jimmy Che-To Lai, Piero Colombatto, Grace Lai-Hung Wong, Maurizia Rossana Brunetto

Digestive and Liver Disease · 2025

DOI: 10.1016/j.dld.2024.10.012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Jimmy Che-To Lai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China; Li Ka Shing Institute …. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B, Chronic, Nucleosides, Withholding Treatment. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral antiviral therapy to hepatitis B virus (HBV) with nucleos(t)ide analogues (NUCs) is effective in suppressing the viral load leading to improved clinical outcomes. However, functional cure of HBV, indicated by hepatitis B surface antigen (HBsAg) clearance from the serum, is rare. Although safety and adherence may represent minor issues in long-term treatment with the available NUCs, more efficacious treatments with finite treatment duration for patients with chronic hepatitis B (CHB) are currently undergoing active clinical investigation. Available data suggest that HBsAg loss can be achieved in 10% to 20% of patients after NUC discontinuation, at the cost of about 50% to 80% virological relapse and 40% to 55% retreatment with NUC. With this, NUC treatment in patients with cirrhosis should not be stopped to avoid detrimental risk of hepatic decompensation and death. Viral and immune biomarkers, which may be potentially useful in stratifying the patients at risk of relapse after stopping NUC therapy, are under investigation. In the era of personalized medicine aided by artificial intelligence tools, tight monitoring of viral kinetics and algorithmic modeling appear a promising strategy to assist in individualized decision and conclude the optimal timing of the NUC treatment discontinuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis B, ChronicNucleosidesWithholding TreatmentHumansHepatitis B Surface AntigensHepatitis B virusViral LoadLiver Cirrhosis

Stichwörter der Autor:innen

Antiviral withdrawalChronic hepatitis BFunctional cure

Substanzen

Antiviral AgentsNucleosidesHepatitis B Surface Antigens

Autor:innen und Institutionen

  • Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, Ch…
  • Liver Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses of Pisa University Hospital.
  • Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China; State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese Unive…
  • Liver Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses of Pisa University Hospital; Department of Clinical and Experimental Medicine, University of Pisa, Italy; Institute of Biostructure and…

Zitieren

APA

Lai, J. C., Colombatto, P., Wong, G. L., & Brunetto, M. R. (2025). Why and when could nucleos(t)ide analogues treatment be withdrawn?. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2024.10.012

Vancouver

Lai JC, Colombatto P, Wong GL, Brunetto MR. Why and when could nucleos(t)ide analogues treatment be withdrawn?. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2024.10.012

BibTeX
@article{Lai2025,
  author = {Lai, Jimmy Che-To and Colombatto, Piero and Wong, Grace Lai-Hung and Brunetto, Maurizia Rossana},
  title = {Why and when could nucleos(t)ide analogues treatment be withdrawn?},
  journal = {Digestive and Liver Disease},
  year = {2025},
  doi = {10.1016/j.dld.2024.10.012}
}
Kostenlos starten →